A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
This is a global, multicenter, randomized Phase 3 study evaluating PF-06821497 (mevrometostat) in combination with enzalutamide versus placebo in combination with enzalutamide in participants with mCRPC where no systemic anti-cancer treatments have been initiated after documentation of mCRPC with the exception of ADT (androgen deprivation therapy) and first-generation anti-androgen agents. Prior treatment with any of the ARSi's enzalutamide, darolutamide, apalutamide, or abiraterone acetate, is not permitted in any setting. Chemotherapy is permitted in the castrate sensitive setting.
This study consists of a Screening Phase, Randomization, Treatment Phase, Safety Follow-up, and Long-Term Follow-up. Participants will be randomized on a 1:1 basis to receive (Arm A) PF-06821497 in combination with enzalutamide, or (Arm B) placebo in combination with enzalutamide.
Inclusion Criteria:
Exclusion Criteria:
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that make the participant inappropriate for the study.
Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
Clinically significant cardiovascular disease.
Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy with a few exceptions.
Participants must be treatment naïve at the mCRPC stage, eg, no cytotoxic chemotherapy, radio-ligand therapy (i.e. 177Lu- PSMA-617), CDK4/6 inhibitors, 5-alpha reductase inhibitors for prostate cancer in any setting, androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment with the following exceptions:
Previous administration with an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is longer).
Inadequate organ function.
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Seattle, Washington 98195, United States
CABA, Buenos Aires C1120AAT, Argentina
Capital Federal, Buenos Aires C1419AHN, Argentina
Mar del Plata, Buenos Aires B7600FZO, Argentina
Capital, Córdoba Province X5008HHW, Argentina
Salvador, Estado de Bahia 41253-190, Brazil
Santo André, São Paulo 09060-650, Brazil
São José do Rio Preto, São Paulo 15090000, Brazil
Beijing, Beijing Municipality 100021, China
Shantou, Guangdong 515000, China
Wuhan, Hubei 430022, China
Nanjing, Jiangsu 210000, China
Hangzhou, Zhejiang 310016, China
Wenzhou, Zhejiang 325000, China
Ostrava - Poruba, Moravian-Silesian Region 708 52, Czechia
Ostrava - Poruba, 708 52, Czechia
Bordeaux, Aquitaine 33076, France
Lyon Cedex08, Auvergne-Rhône-Alpes 69373, France
Strasbourg, Bas-rhin 67098, France
Clermont-Ferrand, 63011, France
Münster, North Rhine-Westphalia 48149, Germany
Chaïdári, Attikí 124 62, Greece
Miskolc, Borsod-Abauj Zemplen county 3526, Hungary
Budapest, Pest County 1122, Hungary
Meldola, Emilia-Romagna 47014, Italy
Rome, Lazio 00168, Italy
Verona, 37134, Italy
Shinjuku-ku, Tokyo 1608582, Japan
Amsterdam, North Holland 1066 CX, Netherlands
Schiedam, South Holland 3118 JH, Netherlands
Krakow, Lesser Poland Voivodeship 30-348, Poland
Krakow, Lesser Poland Voivodeship 31-826, Poland
Wroclaw, Lower Silesian Voivodeship 50-981, Poland
Warsaw, Masovian Voivodeship 02-781, Poland
Koszalin, West Pomeranian Voivodeship 75-581, Poland
Opole, 45-061, Poland
Port Elizabeth, Eastern Cape 6045, South Africa
Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
L'Hospitalet de Llobregat, Catalunya [cataluña] 08908, Spain
Istanbul, İ̇stanbul 34722, Turkey (Türkiye)
Istanbul, İ̇stanbul 34899, Turkey (Türkiye)